Voyager Therapeutics (VYGR) Income from Continuing Operations (2014 - 2026)

Voyager Therapeutics has disclosed Income from Continuing Operations across 13 years of filings, most recently posting 27937000.0 for Q1 2026.

• Income from Continuing Operations for Q1 2026 came in at 27937000.0, up 9.94% year-over-year; the trailing twelve-month figure through Mar 2026 was 116637000.0 (down 37.72% YoY), and the FY2025 annual result was 119721000.0, down 84.18% from the prior year.
• Income from Continuing Operations came in at 27937000.0 for Q1 2026 at Voyager Therapeutics, down from 27426000.0 in the prior quarter.
• In the past five years, Income from Continuing Operations ranged from a high of 124044000.0 in Q1 2023 to a low of 34487000.0 in Q4 2024.
• The 5-year median for Income from Continuing Operations is 22208000.0 (2023), against an average of 7454235.29.
• Across the five-year window, Income from Continuing Operations tumbled 566.69% in 2022 and soared 681.85% in 2023, its largest moves.
• Voyager Therapeutics' Income from Continuing Operations stood at 23610000.0 in 2022, then soared by 338.86% to 56395000.0 in 2023, then tumbled by 161.15% to 34487000.0 in 2024, then gained by 20.47% to 27426000.0 in 2025, then dropped by 1.86% to 27937000.0 in 2026.
• The last three Income from Continuing Operations figures came in at 27937000.0 (Q1 2026), 27426000.0 (Q4 2025), and 27892000.0 (Q3 2025), per Business Quant data.